Consolidated Statements of Operations and comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenues	$ 7,402	$ 7,455
Operating expenses:
Research and development	53,307	54,295
General and administrative	20,836	17,071
Impairment of intangible assets	9,660	513
Total operating expenses	83,803	71,879
Loss from operations	(76,401)	(64,424)
Other income (expense), net:
Investment income, net	1,337	0
Interest expense, net	(968)	0
Other (expense) income, net	(27)	40
Change in fair value of redeemable noncontrolling interests	0	(3,903)
Total other income (expense), net	342	(3,863)
Loss before income taxes	(76,059)	(68,287)
Provision for income taxes	(1,937)	(1)
Net loss	(77,996)	(68,288)
Less: Net loss attributable to the redeemable noncontrolling interests	0	209
Net loss attributable to Ambrx Biopharma Inc. shareholders	$ (77,996)	$ (68,079)
Net loss per share applicable to Ambrx Biopharma Inc. ordinary shareholders-basic	$ (0.29)	$ (0.48)
Net loss per share applicable to Ambrx Biopharma Inc. ordinary shareholders-diluted	$ (0.29)	$ (0.48)
Weighted-average ordinary shares used to compute net loss per share attributable to ordinary shareholders, basic	270,241,698	143,175,224
Weighted-average ordinary shares used to compute net loss per share attributable to ordinary shareholders, diluted	270,241,698	143,175,224
Other comprehensive loss, net of tax:
Net loss	$ (77,996)	$ (68,288)
Foreign currency translation adjustment	0	(18)
Unrealized loss on marketable debt securities, available-for-sale	(512)	0
Total other comprehensive loss	(512)	(18)
Comprehensive loss	(78,508)	(68,306)
Less: Comprehensive loss attributable to the redeemable noncontrolling interests		208
Comprehensive loss attributable to Ambrx Biopharma Inc.	$ (78,508)	$ (68,098)